Enzon Pharmaceuticals, Inc. ENZN OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

64/100

1/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Enzon Pharmaceuticals, Inc. (ENZN) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 58/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

64/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

PAST

50/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

GROWTH

58/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — ENZN

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-7.46

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-0.03	$8.38M	$-1.13M	-13.4%
2017	$0.12	$8.38M	$5.45M	65%
2018	$0.13	$6.92M	$5.85M	84.5%
2019	$-0.02	$207K	$-979K	-472.9%
2020	$-0.03	$52K	$-1.31M	-2521.2%
2021	$-0.03	$701K	$-469K	-66.9%
2022	$-0.02	$26K	$-186K	-715.4%
2023	$0.00	$0.00	$98K	-
2024	$-0.01	$26K	$778K	2992.3%
2025	$-7.46	$0.00	$-3.41M	-